文献速递心境障碍

抗抑郁药联合治疗与抗抑郁药单药治疗急性抑郁症患者的比较:系统综述与Meta分析

Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该系统综述与Meta分析纳入39项随机临床试验共6751例急性抑郁症成人患者,比较抗抑郁药联合治疗与单药治疗。联合治疗在疗效上显著优于单药治疗(SMD=0.31;95%CI,0.19-0.44),其中再摄取抑制剂联合突触前α2自身受体拮抗剂优于其他联合方案(SMD=0.37;95%CI,0.19-0.55),安非他酮联合方案未优于单药治疗(SMD=0.10;95%CI,-0.07至0.27),脱落数及因不良事件脱落数两组无差异。

要点

  • 联合治疗疗效显著优于单药治疗(SMD=0.31;95%CI,0.19-0.44)。
  • 再摄取抑制剂联合突触前α2自身受体拮抗剂优于其他联合方案(SMD=0.37;95%CI,0.19-0.55)。
  • 安非他酮联合方案未优于单药治疗(SMD=0.10;95%CI,-0.07至0.27)。

核心结论

  • 在比较抗抑郁药联合治疗与单药治疗的随机临床试验Meta分析中,联合治疗与更优的治疗结局相关,但未伴随更多患者脱落。
  • 使用突触前α2自身受体拮抗剂的联合方案可能更可取,并可能作为重度抑郁症患者及被认为无应答患者的一线治疗。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、PsycINFO和Cochrane对照试验中心注册库,自各数据库建库至2020年1月。
  • 纳入比较抗抑郁药联合治疗与抗抑郁药单药治疗成人急性抑郁症的随机临床试验,共39项随机临床试验包括6751例患者。
  • 由2名评价者独立进行文献检索、研究选择、数据提取和偏倚风险评估,数据采用随机效应模型合并。

主要发现

  • 联合治疗与单药治疗相比,疗效显著更优(SMD=0.31;95%CI,0.19-0.44)。
  • 再摄取抑制剂联合突触前α2自身受体拮抗剂优于其他联合方案(SMD=0.37;95%CI,0.19-0.55)。
  • 安非他酮联合方案未优于单药治疗(SMD=0.10;95%CI,-0.07至0.27)。
  • 联合治疗与单药治疗的脱落数及因不良事件脱落数无差异。
  • 研究存在异质性,并提示发表偏倚(Egger检验结果阳性;P=0.007,df=36),但结果在预设次要结局及敏感性分析和亚组分析中保持稳健,包括仅限低偏倚风险研究的分析。

临床怎么用

  • 作者认为,使用突触前α2自身受体拮抗剂的联合方案可能更可取,并可能作为重度抑郁症患者及被认为无应答患者的一线治疗。

局限性

  • 研究存在异质性。
  • 提示发表偏倚(Egger检验结果阳性;P=0.007,df=36)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Combining antidepressants is frequently done in the treatment of acute depression, but studies have yielded conflicting results. OBJECTIVE: To conduct a systematic review and meta-analysis assessing efficacy and tolerability of combination therapy. Combinations using presynaptic α2-autoreceptor antagonists or bupropion were investigated separately. DATA SOURCES: MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials were systematically searched from each database inception through January 2020. STUDY SELECTION: Randomized clinical trials (RCTs) comparing combinations of antidepressants with antidepressant monotherapy in adult patients with acute depression were included. DATA EXTRACTION AND SYNTHESIS: Following guidelines from Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and recommendations from the Cochrane Handbook, 2 reviewers independently performed a literature search, study selection, data extraction, and evaluation of risk of bias. Data were pooled in random-effects analyses. MAIN OUTCOMES AND MEASURES: Primary outcome was efficacy measured as standardized mean difference (SMD); secondary outcomes were response, remission, change from baseline in rating scale scores, number of dropouts, and number of dropouts due to adverse events. RESULTS: Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55). Bupropion combinations were not superior to monotherapy (SMD = 0.10; 95% CI, -0.07 to 0.27). Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias (Egger test result was positive; P = .007, df = 36), but results remained robust across prespecified secondary outcomes and sensitivity and subgroup analyses, including analyses restricted to studies with low risk of bias. CONCLUSIONS AND RELEVANCE: In this meta-analysis of RCTs comparing combinations of antidepressants with antidepressant monotherapy, combining antidepressants was associated with superior treatment outcomes but not with more patients dropping out of treatment. Combinations using an antagonist of presynaptic α2-autoreceptors may be preferable and may be applied as a first-line treatment in severe cases of depression and for patients considered nonresponders.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Henssler J, Alexander D, Schwarzer G, et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022. PMID: 35171215. doi:10.1001/jamapsychiatry.2021.4313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。